DK1594972T3 - Transposon-baseret målretningssystem - Google Patents

Transposon-baseret målretningssystem

Info

Publication number
DK1594972T3
DK1594972T3 DK04709603.7T DK04709603T DK1594972T3 DK 1594972 T3 DK1594972 T3 DK 1594972T3 DK 04709603 T DK04709603 T DK 04709603T DK 1594972 T3 DK1594972 T3 DK 1594972T3
Authority
DK
Denmark
Prior art keywords
poly
domain
transposase
peptide
transposon
Prior art date
Application number
DK04709603.7T
Other languages
English (en)
Inventor
Zoltan Ivics
Zsuzsanna Izsvak
Original Assignee
Max Delbrueck Centrum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Delbrueck Centrum filed Critical Max Delbrueck Centrum
Application granted granted Critical
Publication of DK1594972T3 publication Critical patent/DK1594972T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
DK04709603.7T 2003-02-10 2004-02-10 Transposon-baseret målretningssystem DK1594972T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03002637 2003-02-10
PCT/EP2004/001220 WO2004069994A2 (en) 2003-02-10 2004-02-10 Transposon-based targeting system

Publications (1)

Publication Number Publication Date
DK1594972T3 true DK1594972T3 (da) 2011-04-18

Family

ID=32842694

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04709603.7T DK1594972T3 (da) 2003-02-10 2004-02-10 Transposon-baseret målretningssystem

Country Status (7)

Country Link
US (1) US20080008687A1 (da)
EP (1) EP1594972B1 (da)
JP (1) JP2006518203A (da)
AT (1) ATE498016T1 (da)
DE (1) DE602004031325D1 (da)
DK (1) DK1594972T3 (da)
WO (1) WO2004069994A2 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2067402A1 (en) 2007-12-07 2009-06-10 Max Delbrück Centrum für Molekulare Medizin (MDC) Berlin-Buch; Transponson-mediated mutagenesis in spermatogonial stem cells
EP2369916A4 (en) 2008-12-01 2013-04-10 Univ Texas PREPARATION AND USE OF SPERMATOGONIAL STEM CELL LINES FROM THE RAT
US10689643B2 (en) 2011-11-22 2020-06-23 Active Motif, Inc. Targeted transposition for use in epigenetic studies
EP2740353A1 (en) 2012-12-06 2014-06-11 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel inducible animal models of stress behavior
WO2014143383A1 (en) * 2013-03-13 2014-09-18 Agilent Technologies, Inc. Transposome tethered to a gene delivery vehicle
US11278570B2 (en) 2016-12-16 2022-03-22 B-Mogen Biotechnologies, Inc. Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
CA3047313A1 (en) 2016-12-16 2018-06-21 B-Mogen Biotechnologies, Inc. Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods
WO2018195129A1 (en) 2017-04-17 2018-10-25 University Of Maryland, College Park Embryonic cell cultures and methods of using the same
WO2019246486A2 (en) 2018-06-21 2019-12-26 B-Mogen Biotechnologies, Inc. ENHANCED hAT FAMILY TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODS
EP3856224A4 (en) * 2018-09-25 2022-07-06 Emory University NUCLEIC ACIDS FOR RECOGNITION AND INTEGRATION OF CELLS
CA3126773A1 (en) * 2019-02-13 2020-08-20 Probiogen Ag Transposase with enhanced insertion site selection properties
CN110776570A (zh) * 2019-10-22 2020-02-11 上海海洋大学 一种重组转座酶及其用途
EP4182341A1 (en) 2020-07-17 2023-05-24 ProBioGen AG Hyperactive transposons and transposases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7097494A (en) * 1993-06-01 1994-12-20 Targeted Genetics Corporation Envelope fusion vectors for use in gene delivery
CA2280997C (en) * 1997-03-11 2013-05-28 Perry B. Hackett Dna-based transposon system for the introduction of nucleic acid into dna of a cell
US5958775A (en) * 1997-07-25 1999-09-28 Thomas Jefferson University Composition and method for targeted integration into cells
AU1100201A (en) * 1999-10-28 2001-05-08 Board Of Trustees Of The Leland Stanford Junior University Methods of in vivo gene transfer using a sleeping beauty transposon system
EP1303608A2 (en) * 2000-07-21 2003-04-23 Syngenta Participations AG Zinc finger domain recognition code and uses thereof
DE60335637D1 (de) * 2002-07-24 2011-02-17 Manoa Biosciences Inc Vektoren auf transposonbasis und verfahren zur integration von nukleinsäuren

Also Published As

Publication number Publication date
EP1594972B1 (en) 2011-02-09
US20080008687A1 (en) 2008-01-10
WO2004069994A3 (en) 2004-10-28
DE602004031325D1 (de) 2011-03-24
EP1594972A2 (en) 2005-11-16
WO2004069994A2 (en) 2004-08-19
ATE498016T1 (de) 2011-02-15
JP2006518203A (ja) 2006-08-10

Similar Documents

Publication Publication Date Title
DK1594973T3 (da) Transposonbaseret målretningssystem
DK1594971T3 (da) Transposonbaseret målretningssystem
SG162687A1 (en) Caustic stable chromatography ligands
DK1594972T3 (da) Transposon-baseret målretningssystem
WO2007140505A3 (en) Vaccine carrier
HK1125387A1 (en) Compositions and methods for fusion protein separation
EP2185197A4 (en) NOVEL COMPOSITIONS OF A SOLUTION CONTAINING A CELLULAR FACTOR
WO2007081851A3 (en) Affinity chromatography matrices and methods of making and using the same
SG159458A1 (en) Novel immunoglobulin-binding proteins with improved specificity
NI200900097A (es) FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLÓGICA MEJORADA.
WO2004099231A3 (en) Glycopegylation methods and proteins/peptides produced by the methods
NZ598770A (en) Monoclonal antibodies
EA200700917A1 (ru) Способ рефолдинга рекомбинантных антител
WO2007115571A8 (en) Erbb receptor-derived peptide fragments
NZ583783A (en) Avian interferon-lambda polypeptide and genetic sequences encoding the same
ATE501268T1 (de) Vorrichtungen und verfahren zur bestimmung von proteaseaktivität
TW200745159A (en) IL-6 binding proteins
WO2006132739A3 (en) Novel chemical compounds
DK1519944T3 (da) Fremgangsmåder til fremstilling af fibrinogen
WO2009025300A1 (ja) イミュノグロブリン結合能を有するペプチド
WO2010142551A8 (en) Amino acid sequences directed against receptors to cytokines belonging to the il-17 family
WO2007045019A3 (en) Polyoleosins
IL175646A0 (en) Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof
WO2009131698A3 (en) PHOSPHORYLATED RECOMBINANT N-ACETYL-alpha-D- GLUCOSAMINIDASE (NaGlu) AND USES THEREOF
WO2007014076A3 (en) Methods of producing modified assembly lines and related compositions